NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Targeted Microbiome Transplant in Atopic Dermatitis

Phase 1

Completed

Conditions: Atopic Dermatitis (AD)

Interventions: Biological: TMT Lotion
Drug: Placebo Lotion

First Posted Date: 2017-05-12

Last Posted Date: 2020-08-17

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 54

Registration Number: NCT03151148

Locations: 🇺🇸
University of California - San Diego, San Diego, California, United States
🇺🇸
National Jewish Health General Clinical Research Center, Denver, Colorado, United States

Evaluating the Pharmacokinetics, Safety, and Tolerability of Delamanid in Combination With Optimized Multidrug Background Regimen (OBR) for Multidrug-Resistant Tuberculosis (MDR-TB) in HIV-Infected and HIV-Uninfected Children With MDR-TB

Phase 1

Active, not recruiting

Conditions: Tuberculosis
HIV Infections

Interventions: Drug: Delamanid
Drug: Optimized multidrug background regimen (OBR) for children with MDR-TB

First Posted Date: 2017-05-04

Last Posted Date: 2024-12-13

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 37

Registration Number: NCT03141060

Locations: 🇮🇳
Byramjee Jeejeebhoy Medical College (BJMC) CRS, Pune, Maharashtra, India
🇿🇦
Sizwe CRS, Johannesburg, Gauteng, South Africa
🇿🇦
PHRU Matlosana CRS, Klerksdorp, North West Province, South Africa

and more 2 locations

Evaluating the Safety and Immunogenicity of ALVAC-HIV and MF59®- or AS01B-adjuvanted Bivalent Subtype C gp120 in Healthy, HIV-uninfected Adult Participants

Phase 1

Completed

Conditions: HIV Infections

Interventions: Biological: ALVAC-HIV (vCP2438)
Biological: Bivalent subtype C gp120/MF59
Biological: Bivalent subtype C gp120/AS01(B)
Biological: Placebo

First Posted Date: 2017-04-20

Last Posted Date: 2023-03-14

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 160

Registration Number: NCT03122223

Locations: 🇺🇸
Fenway Health (FH) CRS, Boston, Massachusetts, United States
🇺🇸
Vanderbilt Vaccine (VV) CRS, Nashville, Tennessee, United States
🇺🇸
Bridge HIV CRS, San Francisco, California, United States

and more 9 locations

Targeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS)

Phase 1

Recruiting

Conditions: Multiple Sclerosis

Interventions: Drug: Pioglitazone
Drug: clemastine fumarate
Drug: Dantrolene
Drug: Pirfenidone

First Posted Date: 2017-04-12

Last Posted Date: 2024-12-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 250

Registration Number: NCT03109288

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents

Phase 2

Completed

Conditions: Zika Virus Infection
Flaviviral Diseases
Virus Diseases
RNA Virus Infections
Zika Virus
Flavivirus Infections
Flaviviridae Infections

Interventions: Biological: VRC-ZKADNA090-00-VP
Other: VRC-PBSPLA043-00-VP

First Posted Date: 2017-04-12

Last Posted Date: 2024-01-31

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 2428

Registration Number: NCT03110770

Locations: 🇵🇦
Instituto Conmemorativo Gorgas, Panamá, San Miguelito Province, Panama
🇵🇷
Puerto Rico Clinical and Translational Research Consortium, San Juan, Puerto Rico
🇨🇴
Clinica de la Costa Ltda, Barranquilla, Atlantico, Colombia

and more 14 locations

A Phase Ib Study of the Safety, Reactogenicity, and Immunogenicity of Sm-TSP-2/Alhydrogel)(R) With or Without AP 10-701 for Intestinal Schistosomiasis in Healthy Exposed Adults

Phase 1

Completed

Conditions: Schistosomiasis

Interventions: Biological: Sm-TSP-2/Alhydrogel
Biological: GLA-AF
Biological: Hepatitis B Virus Vaccine (Recombinant)

First Posted Date: 2017-04-12

Last Posted Date: 2021-02-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 60

Registration Number: NCT03110757

Locations: 🇧🇷
Americaninhas Vaccine Center, Novo Oriente, Minas Gerais, Brazil

Evaluating the Infectivity, Safety, and Immunogenicity of a Single Dose of a Recombinant Live-Attenuated Respiratory Syncytial Virus Vaccine (D46/NS2/N/ΔM2-2-HindIII) in RSV-Seronegative Infants 6 to 24 Months of Age

Phase 1

Completed

Conditions: Respiratory Syncytial Virus Infections

Interventions: Biological: D46/NS2/N/ΔM2-2-HindIII
Biological: Placebo

First Posted Date: 2017-04-05

Last Posted Date: 2022-02-08

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 32

Registration Number: NCT03102034

Locations: 🇺🇸
Usc La Nichd Crs, Los Angeles, California, United States
🇺🇸
Univ. of Colorado Denver NICHD CRS, Aurora, Colorado, United States
🇺🇸
David Geffen School of Medicine at UCLA NICHD CRS, Los Angeles, California, United States

and more 7 locations

PREVAIL VI: Identification of Host Genetic Factors Underlying Ebola Virus Disease Risk, Mortality, Long-term Sequelae, Viral RNA Persistence, Humoral Immunity, and Ebola Vaccine Response

Completed

Conditions: Ebola Virus Disease

First Posted Date: 2017-04-04

Last Posted Date: 2022-08-22

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 4830

Registration Number: NCT03098862

Locations: 🇱🇷
PREVAIL C. H. Rennie Hospital, Kalkata, Liberia
🇱🇷
PREVAIL JFK Medical Center, Monrovia, Liberia
🇱🇷
PREVAIL Duport Road Clinic, Paynesville, Liberia

and more 1 locations

JBT-101 in Systemic Lupus Erythematosus (SLE)

Phase 2

Completed

Conditions: Systemic Lupus Erythematosus
Lupus
SLE

Interventions: Drug: JBT-101
Drug: Placebo

First Posted Date: 2017-03-28

Last Posted Date: 2022-11-18

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 109

Registration Number: NCT03093402

Locations: 🇺🇸
Temple University, Philadelphia, Pennsylvania, United States
🇺🇸
Yale University, New Haven, Connecticut, United States
🇺🇸
Duke University, Durham, North Carolina, United States

and more 13 locations

Herpesviruses Reactivation In Hiv-Infected Women Initiating ART (HERA)

Completed

Conditions: Herpes Virus-Related Illnesses

First Posted Date: 2017-03-28

Last Posted Date: 2024-02-02

Lead Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)

Target Recruit Count: 190

Registration Number: NCT03092505

Locations: 🇺🇬
Rakai, Kalisizo, and Villa Maria Hospital, Kalisizo, Uganda
🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy